Quadrant Capital Group LLC Seagen Inc. Transaction History

Quadrant Capital Group LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $574 - $648	3 Added 0.84%	362 $76,000
Q2 2023 Aug 09, 2023	SELL	$187.64 - $206.25 $14,260 - $15,675	-76 Reduced 17.47%	359 $69,000
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $24,624 - $39,194	193 Added 79.75%	435 $88,000
Q4 2022 Feb 10, 2023	SELL	$117.37 - $139.17 $15,844 - $18,787	-135 Reduced 35.81%	242 $31,000
Q3 2022 Nov 10, 2022	SELL	$135.27 - $180.11 $21,372 - $28,457	-158 Reduced 29.53%	377 $52,000
Q2 2022 Aug 09, 2022	SELL	$108.81 - $179.33 $9,466 - $15,601	-87 Reduced 13.99%	535 $95,000
Q1 2022 May 06, 2022	BUY	$119.61 - $157.85 $20,453 - $26,992	171 Added 37.92%	622 $90,000
Q4 2021 Feb 01, 2022	SELL	$142.57 - $190.86 $23,951 - $32,064	-168 Reduced 27.14%	451 $70,000
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $33,333 - $39,737	234 Added 60.78%	619 $105,000
Q2 2021 Aug 09, 2021	BUY	$135.08 - $161.1 $1,891 - $2,255	14 Added 3.77%	385 $61,000
Q1 2021 May 12, 2021	BUY	$137.51 - $190.8 $4,400 - $6,105	32 Added 9.44%	371 $52,000
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $55,809 - $71,844	339 New	339 $59,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.